Emerging agents for the treatment of metastatic urothelial cancer
Over the past few decades, platinum-based combination chemotherapy (PBCC) has been the preferred initial therapy for metastatic urothelial cancer (mUC). However, despite a response rate of approximately 50%, a small proportion of patients with distant metastases may be cured by cisplatin-based combi...
| Hlavní autoři: | , |
|---|---|
| Médium: | Článek |
| Jazyk: | English |
| Vydáno: |
Korean Urological Association
2021-05-01
|
| Edice: | Investigative and Clinical Urology |
| Témata: | |
| On-line přístup: | https://www.icurology.org/pdf/10.4111/icu.20200597 |